Trial Profile
Dabigatran Study in the Early Phase of Stroke. New Neuroimaging Markers and Biomarkers Study (SEDMAN STUDY)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Mar 2022
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Acenocoumarol
- Indications Embolism; Stroke
- Focus Adverse reactions; Therapeutic Use
- Acronyms SEDMAN
- 25 Feb 2022 Data was used from GRECOS (Genotyping Recurrence Risk of Stroke) and SEDMAN (Dabigatran Study in the Early Phase of Stroke, New Neuroimaging Markers and Biomarkers) studies to assess biological age acceleration in Women with ischemic stroke compared to men published in the Stroke
- 19 Mar 2018 Planned primary completion date changed from 1 Apr 2017 to 1 Jun 2019.
- 19 Mar 2018 Status changed from not yet recruiting to recruiting.